: Non-Hodgkin lymphomas represents a heterogeneous group of lymphoproliferative disorders characterized by different clinical courses, varying from indolent to highly aggressive. 18F-FDG-PET/CT is the current state-of-the-art diagnostic imaging, for the staging, restaging and evaluation of response to treatment in lymphomas with avidity for 18F-FDG, despite it is not routinely recommended for surveillance. PET-based response criteria (using five-point Deauville Score) are nowadays uniformly applied in FDG-avid lymphomas. In this review, a comprehensive overview of the role of 18F-FDG-PET in Non-Hodgkin lymphomas is provided, at each relevant point of patient management, particularly focusing on recent advances on diffuse large B-cell lymphoma and follicular lymphoma, with brief updates also on other histotypes (such as marginal zone, mantle cell, primary mediastinal- B cell lymphoma and T cell lymphoma). PET-derived semiquantitative factors useful for patient stratification and prognostication and emerging radiomics research are also presented.

Zanoni L., Bezzi D., Nanni C., Paccagnella A., Farina A., Broccoli A., et al. (2022). PET/CT in Non-Hodgkin Lymphoma: An Update. SEMINARS IN NUCLEAR MEDICINE, S0001-2998, 96-96 [10.1053/j.semnuclmed.2022.11.001].

PET/CT in Non-Hodgkin Lymphoma: An Update

Bezzi D.;Paccagnella A.;Broccoli A.;Zinzani P. L.;Fanti S.
2022

Abstract

: Non-Hodgkin lymphomas represents a heterogeneous group of lymphoproliferative disorders characterized by different clinical courses, varying from indolent to highly aggressive. 18F-FDG-PET/CT is the current state-of-the-art diagnostic imaging, for the staging, restaging and evaluation of response to treatment in lymphomas with avidity for 18F-FDG, despite it is not routinely recommended for surveillance. PET-based response criteria (using five-point Deauville Score) are nowadays uniformly applied in FDG-avid lymphomas. In this review, a comprehensive overview of the role of 18F-FDG-PET in Non-Hodgkin lymphomas is provided, at each relevant point of patient management, particularly focusing on recent advances on diffuse large B-cell lymphoma and follicular lymphoma, with brief updates also on other histotypes (such as marginal zone, mantle cell, primary mediastinal- B cell lymphoma and T cell lymphoma). PET-derived semiquantitative factors useful for patient stratification and prognostication and emerging radiomics research are also presented.
2022
Zanoni L., Bezzi D., Nanni C., Paccagnella A., Farina A., Broccoli A., et al. (2022). PET/CT in Non-Hodgkin Lymphoma: An Update. SEMINARS IN NUCLEAR MEDICINE, S0001-2998, 96-96 [10.1053/j.semnuclmed.2022.11.001].
Zanoni L.; Bezzi D.; Nanni C.; Paccagnella A.; Farina A.; Broccoli A.; Casadei B.; Zinzani P.L.; Fanti S.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/915076
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 19
  • ???jsp.display-item.citation.isi??? ND
social impact